Literature DB >> 1281455

Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cells.

C Oetken1, M von Willebrand, M Autero, T Ruutu, L C Andersson, T Mustelin.   

Abstract

Tyrosine phosphorylation and dephosphorylation are implicated in the regulation of cell growth and differentiation. A diverse identification of key regulatory proteins by their content of phosphotyrosine has been hampered by the very low level of tyrosine phosphorylation. This is presumably caused by the relative preponderance of phosphotyrosine phosphatase activity in many cells. We report that treatment of hematopoietic cells with phenylarsine oxide (PAO), a membrane-permeable phosphotyrosine phosphatase inhibitor, induced a dramatic accumulation of phosphotyrosine in a number of cellular proteins. No changes in serine or threonine phosphorylation were detected. The PAO-induced accumulation of phosphotyrosine occurred well before any signs of toxicity or irreversible damage to the cells were seen. Addition of dithiothreitol reversed the effect of PAO. Our data demonstrate that phosphotyrosine phosphatase activity has a major impact on the level of phosphotyrosine in cellular proteins, even in cells with high protein tyrosine kinase activity. Cells with constitutively elevated tyrosine kinase activity are easily detected following treatment with PAO and substrates with an otherwise too low phosphotyrosine content or too rapid phosphate turnover can be studied. This effect of PAO allows determinations of tyrosine phosphorylation-dependent complex formation between proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281455     DOI: 10.1111/j.1600-0609.1992.tb00048.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

1.  Oxidative stress triggers tyrosine phosphorylation in B cells through a redox- and inflammatory cytokine-sensitive mechanism.

Authors:  Y Suzuki; K Ohsugi; Y Ono
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

Review 2.  Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications.

Authors:  Sabrina Solouki; Avery August; Weishan Huang
Journal:  Pharmacol Ther       Date:  2019-05-11       Impact factor: 12.310

3.  Tyrosine phosphorylation of CD45 phosphotyrosine phosphatase by p50csk kinase creates a binding site for p56lck tyrosine kinase and activates the phosphatase.

Authors:  M Autero; J Saharinen; T Pessa-Morikawa; M Soula-Rothhut; C Oetken; M Gassmann; M Bergman; K Alitalo; P Burn; C G Gahmberg
Journal:  Mol Cell Biol       Date:  1994-02       Impact factor: 4.272

4.  Hematopoietic protein tyrosine phosphatase mediates beta2-adrenergic receptor-induced regulation of p38 mitogen-activated protein kinase in B lymphocytes.

Authors:  Jaclyn W McAlees; Virginia M Sanders
Journal:  Mol Cell Biol       Date:  2008-12-01       Impact factor: 4.272

5.  Amplification of the inflammatory cellular redox state by human immunodeficiency virus type 1-immunosuppressive tat and gp160 proteins.

Authors:  A Lachgar; N Sojic; S Arbault; D Bruce; A Sarasin; C Amatore; B Bizzini; D Zagury; M Vuillaume
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Activation of p56lck by p72syk through physical association and N-terminal tyrosine phosphorylation.

Authors:  C Couture; G Baier; C Oetken; S Williams; D Telford; A Marie-Cardine; G Baier-Bitterlich; S Fischer; P Burn; A Altman
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

7.  Molecular profiling of signalling proteins for effects induced by the anti-cancer compound GSAO with 400 antibodies.

Authors:  Verity A Cadd; Philip J Hogg; Adrian L Harris; Stephan M Feller
Journal:  BMC Cancer       Date:  2006-06-09       Impact factor: 4.430

8.  Tyrosine Dephosphorylation of ASC Modulates the Activation of the NLRP3 and AIM2 Inflammasomes.

Authors:  Bezaleel Mambwe; Kurt Neo; Hanif Javanmard Khameneh; Keith Weng Kit Leong; Mariasilvia Colantuoni; Maurizio Vacca; Richmond Muimo; Alessandra Mortellaro
Journal:  Front Immunol       Date:  2019-07-05       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.